Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Placenta-Specific Genes, Their Regulation During Villous Trophoblast Differentiation and Dysregulation in Preterm Preeclampsia.

Szilagyi A, Gelencser Z, Romero R, Xu Y, Kiraly P, Demeter A, Palhalmi J, Gyorffy BA, Juhasz K, Hupuczi P, Kekesi KA, Meinhardt G, Papp Z, Draghici S, Erez O, Tarca AL, Knöfler M, Than NG.

Int J Mol Sci. 2020 Jan 17;21(2). pii: E628. doi: 10.3390/ijms21020628.

2.

Theory of mind development from adolescence to adulthood: Testing the two-component model.

Meinhardt-Injac B, Daum MM, Meinhardt G.

Br J Dev Psychol. 2020 Jan 20. doi: 10.1111/bjdp.12320. [Epub ahead of print]

PMID:
31960462
3.

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.

Huillard O, Jouinot A, Tlemsani C, Brose MS, Arrondeau J, Meinhardt G, Fellous M, De Sanctis Y, Schlumberger M, Goldwasser F.

Thyroid. 2019 Dec;29(12):1820-1827. doi: 10.1089/thy.2018.0784.

4.

Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.

Brose MS, Schlumbeger M, Jeffers M, Kappeler C, Meinhardt G, Peña CEA.

Clin Cancer Res. 2019 Dec 15;25(24):7370-7380. doi: 10.1158/1078-0432.CCR-18-3439. Epub 2019 Sep 26.

PMID:
31558473
5.

A Systematic Approach for Post Hoc Subgroup Analyses With Applications in Clinical Case Studies.

Muysers C, Dmitrienko A, Kulmann H, Kirsch B, Lippert S, Schmelter T, Schulz A, Mentenich N, Schmitz H, Schaefers M, Meinhardt G, Keil T, Roll S.

Ther Innov Regul Sci. 2019 Jun 16:2168479019853782. doi: 10.1177/2168479019853782. [Epub ahead of print]

PMID:
31204501
6.

Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.

Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA.

Clin Transl Sci. 2019 Sep;12(5):459-469. doi: 10.1111/cts.12634. Epub 2019 Apr 12.

7.

Orientation-invariance of individual differences in three face processing tasks.

Meinhardt G, Meinhardt-Injac B, Persike M.

R Soc Open Sci. 2019 Jan 9;6(1):181350. doi: 10.1098/rsos.181350. eCollection 2019 Jan.

8.

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.

Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J.

Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.

9.

Genome amplification and cellular senescence are hallmarks of human placenta development.

Velicky P, Meinhardt G, Plessl K, Vondra S, Weiss T, Haslinger P, Lendl T, Aumayr K, Mairhofer M, Zhu X, Schütz B, Hannibal RL, Lindau R, Weil B, Ernerudh J, Neesen J, Egger G, Mikula M, Röhrl C, Urban AE, Baker J, Knöfler M, Pollheimer J.

PLoS Genet. 2018 Oct 12;14(10):e1007698. doi: 10.1371/journal.pgen.1007698. eCollection 2018 Oct.

10.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.

Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM.

Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.

11.

Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].

Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J.

J Hepatol. 2018 Oct;69(4):990-991. doi: 10.1016/j.jhep.2018.07.015. Epub 2018 Aug 10. No abstract available.

PMID:
30104026
12.

Self-Renewing Trophoblast Organoids Recapitulate the Developmental Program of the Early Human Placenta.

Haider S, Meinhardt G, Saleh L, Kunihs V, Gamperl M, Kaindl U, Ellinger A, Burkard TR, Fiala C, Pollheimer J, Mendjan S, Latos PA, Knöfler M.

Stem Cell Reports. 2018 Aug 14;11(2):537-551. doi: 10.1016/j.stemcr.2018.07.004. Epub 2018 Aug 2.

13.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.

J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.

PMID:
29704513
14.

External and internal facial features modulate processing of vertical but not horizontal spatial relations.

Meinhardt G, Kurbel D, Meinhardt-Injac B, Persike M.

Vision Res. 2019 Apr;157:44-54. doi: 10.1016/j.visres.2017.12.006. Epub 2018 Mar 22.

PMID:
29567098
15.

The Two-Systems Account of Theory of Mind: Testing the Links to Social- Perceptual and Cognitive Abilities.

Meinhardt-Injac B, Daum MM, Meinhardt G, Persike M.

Front Hum Neurosci. 2018 Jan 31;12:25. doi: 10.3389/fnhum.2018.00025. eCollection 2018.

16.

On Response Bias in the Face Congruency Effect for Internal and External Features.

Meinhardt G, Meinhardt-Injac B, Persike M.

Front Hum Neurosci. 2017 Oct 17;11:494. doi: 10.3389/fnhum.2017.00494. eCollection 2017.

17.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

18.

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J.

J Hepatol. 2017 Nov;67(5):999-1008. doi: 10.1016/j.jhep.2017.06.026. Epub 2017 Jul 4. Erratum in: J Hepatol. 2018 Oct;69(4):990-991.

19.

Object Localization Does Not Imply Awareness of Object Category at the Break of Continuous Flash Suppression.

Kobylka F, Persike M, Meinhardt G.

Front Hum Neurosci. 2017 Jun 15;11:312. doi: 10.3389/fnhum.2017.00312. eCollection 2017.

20.

Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.

Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, Bruix J, Meinhardt G, Cleton A, Ploeger B.

Eur J Pharm Sci. 2017 Nov 15;109S:S149-S153. doi: 10.1016/j.ejps.2017.05.050. Epub 2017 May 23.

21.

Chymase-producing cells of the innate immune system are required for decidual vascular remodeling and fetal growth.

Meyer N, Woidacki K, Knöfler M, Meinhardt G, Nowak D, Velicky P, Pollheimer J, Zenclussen AC.

Sci Rep. 2017 Mar 22;7:45106. doi: 10.1038/srep45106.

22.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
23.

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.

Lin SM, Lu SN, Chen PT, Jeng LB, Chen SC, Hu CT, Yang SS, Le Berre MA, Liu X, Mitchell DY, Prins K, Grevel J, Peña CA, Meinhardt G.

Hepatol Int. 2017 Mar;11(2):199-208. doi: 10.1007/s12072-016-9774-x. Epub 2016 Dec 1.

24.

Notch1 controls development of the extravillous trophoblast lineage in the human placenta.

Haider S, Meinhardt G, Saleh L, Fiala C, Pollheimer J, Knöfler M.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7710-E7719. Epub 2016 Nov 14.

25.

From development to aging: Holistic face perception in children, younger and older adults.

Meinhardt-Injac B, Boutet I, Persike M, Meinhardt G, Imhof M.

Cognition. 2017 Jan;158:134-146. doi: 10.1016/j.cognition.2016.10.020. Epub 2016 Nov 9.

PMID:
27835784
26.

Contextual Interactions in Grating Plaid Configurations Are Explained by Natural Image Statistics and Neural Modeling.

Ernst UA, Schiffer A, Persike M, Meinhardt G.

Front Syst Neurosci. 2016 Oct 4;10:78. eCollection 2016.

27.

The Composite Effect Is Face-Specific in Young but Not Older Adults.

Meinhardt G, Persike M, Meinhardt-Injac B.

Front Aging Neurosci. 2016 Aug 5;8:187. doi: 10.3389/fnagi.2016.00187. eCollection 2016.

28.

Contour integration with corners.

Persike M, Meinhardt G.

Vision Res. 2016 Oct;127:132-140. doi: 10.1016/j.visres.2016.07.010. Epub 2016 Aug 31.

29.

Wingless ligand 5a is a critical regulator of placental growth and survival.

Meinhardt G, Saleh L, Otti GR, Haider S, Velicky P, Fiala C, Pollheimer J, Knöfler M.

Sci Rep. 2016 Jun 17;6:28127. doi: 10.1038/srep28127.

30.

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.

Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, Peña CE.

Clin Cancer Res. 2016 Oct 1;22(19):4870-4879. Epub 2016 May 24.

31.

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.

J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.

PMID:
26809111
32.

The preview benefit in single-feature and conjunction search: Constraints of visual marking.

Meinhardt G, Persike M.

J Vis. 2015;15(13):13. doi: 10.1167/15.13.13.

33.

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.

Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS.

Endocr Relat Cancer. 2015 Dec;22(6):877-87. doi: 10.1530/ERC-15-0252.

34.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators.

Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.

PMID:
26361969
35.

The sensitivity to replacement and displacement of the eyes region in early adolescence, young and later adulthood.

Meinhardt-Injac B, Persike M, Imhof M, Meinhardt G.

Front Psychol. 2015 Aug 11;6:1164. doi: 10.3389/fpsyg.2015.01164. eCollection 2015.

36.

ERBB2 gene amplification increases during the transition of proximal EGFR(+) to distal HLA-G(+) first trimester cell column trophoblasts.

Meinhardt G, Kaltenberger S, Fiala C, Knöfler M, Pollheimer J.

Placenta. 2015 Aug;36(8):803-8. doi: 10.1016/j.placenta.2015.05.017. Epub 2015 Jun 6.

37.

Cue combination anisotropies in contour integration: The role of lower spatial frequencies.

Persike M, Meinhardt G.

J Vis. 2015;15(5):17. doi: 10.1167/15.5.17.

38.

Effects of Spatial Frequency Similarity and Dissimilarity on Contour Integration.

Persike M, Meinhardt G.

PLoS One. 2015 Jun 9;10(6):e0126449. doi: 10.1371/journal.pone.0126449. eCollection 2015.

39.

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK.

J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29.

40.

The complete design in the composite face paradigm: role of response bias, target certainty, and feedback.

Meinhardt G, Meinhardt-Injac B, Persike M.

Front Hum Neurosci. 2014 Oct 31;8:885. doi: 10.3389/fnhum.2014.00885. eCollection 2014.

41.

Holistic face perception in young and older adults: effects of feedback and attentional demand.

Meinhardt-Injac B, Persike M, Meinhardt G.

Front Aging Neurosci. 2014 Oct 22;6:291. doi: 10.3389/fnagi.2014.00291. eCollection 2014.

42.

Holistic processing and reliance on global viewing strategies in older adults' face perception.

Meinhardt-Injac B, Persike M, Meinhardt G.

Acta Psychol (Amst). 2014 Sep;151:155-63. doi: 10.1016/j.actpsy.2014.06.001. Epub 2014 Jun 28.

PMID:
24977938
43.

Development of visual systems for faces and objects: further evidence for prolonged development of the face system.

Meinhardt-Injac B, Persike M, Meinhardt G.

PLoS One. 2014 Jun 23;9(6):e99942. doi: 10.1371/journal.pone.0099942. eCollection 2014.

44.

The face inversion effect in opponent-stimulus rivalry.

Persike M, Meinhardt-Injac B, Meinhardt G.

Front Hum Neurosci. 2014 May 15;8:295. doi: 10.3389/fnhum.2014.00295. eCollection 2014.

45.

Integration of internal and external facial features in 8- to 10-year-old children and adults.

Meinhardt-Injac B, Persike M, Meinhardt G.

Acta Psychol (Amst). 2014 Jun;149:96-105. doi: 10.1016/j.actpsy.2014.03.008.

PMID:
24769271
46.

Wnt-dependent T-cell factor-4 controls human etravillous trophoblast motility.

Meinhardt G, Haider S, Haslinger P, Proestling K, Fiala C, Pollheimer J, Knöfler M.

Endocrinology. 2014 May;155(5):1908-20. doi: 10.1210/en.2013-2042. Epub 2014 Feb 26.

PMID:
24605829
47.

Holistic face processing is induced by shape and texture.

Meinhardt-Injac B, Persike M, Meinhardt G.

Perception. 2013;42(7):716-32.

PMID:
24344548
48.

Notch signaling plays a critical role in motility and differentiation of human first-trimester cytotrophoblasts.

Haider S, Meinhardt G, Velicky P, Otti GR, Whitley G, Fiala C, Pollheimer J, Knöfler M.

Endocrinology. 2014 Jan;155(1):263-74. doi: 10.1210/en.2013-1455. Epub 2013 Dec 20.

PMID:
24189144
49.

The preview benefit for familiar and unfamiliar faces.

Persike M, Meinhardt-Injac B, Meinhardt G.

Vision Res. 2013 Jul 19;87:1-9. doi: 10.1016/j.visres.2013.05.005. Epub 2013 May 18.

50.

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group.

Br J Cancer. 2012 Sep 25;107(7):1044-50. doi: 10.1038/bjc.2012.369. Epub 2012 Aug 21.

Supplemental Content

Loading ...
Support Center